Retatrutide Knee Osteoarthritis Pain Relief Weight Loss Phase 3

The TRIUMPH-4 phase 3 trial of retatrutide knee osteoarthritis pain relief weight loss phase 3 delivered impressive results for patients with obesity and knee pain. Participants on the highest dose lost up to 28.7% of their body weight, or about 71 pounds on average,[1][2] while seeing a 75.8% drop in knee pain scores.[1][2] These findings highlight retatrutide's potential as a dual-benefit treatment, but safety concerns like dysesthesia need monitoring as it advances.[1][2]

Introduction to Retatrutide Knee Osteoarthritis Pain Relief Weight Loss Phase 3

Retatrutide, an investigational drug from Eli Lilly,[1][2] targets obesity and knee osteoarthritis (OA) together. The TRIUMPH-4 trial tested it in people without diabetes,[1] showing strong results in weight loss and pain relief. This approach could change how doctors treat knee OA, where extra weight worsens joint stress. The retatrutide knee osteoarthritis pain relief weight loss phase 3 study provides key data on this promising combo.

Overview of the TRIUMPH-4 Trial (NCT05931367)

TRIUMPH-4 (NCT05931367)[1] is a key study in Eli Lilly's TRIUMPH phase 3 program. It enrolled 445 adults with obesity or overweight plus knee OA.[1] Topline results came in December 2025,[1][2] with full data updates in early 2026.[1] ClinicalTrials.gov.

The trial ran about 77 weeks, focusing on changes at week 68.[1] It used a randomized, double-blind design against placebo.[1] Patients followed diet and exercise alongside treatment.

Why Weight Loss Matters for Knee Osteoarthritis Pain Relief

Extra body weight puts huge pressure on knee joints—each pound of fat adds 4 pounds of force per step. Losing weight eases this load, reducing pain and improving mobility. In knee OA, studies show 10% weight loss can cut pain by half for many patients. Knee OA weight loss guide.

Retatrutide knee osteoarthritis pain relief weight loss phase 3 builds on this by combining powerful weight reduction with direct joint benefits. Past trials with drugs like semaglutide showed 42% pain drops, but retatrutide went further.[2]

Retatrutide as a Triple Hormone Agonist: GIP, GLP-1, and Glucagon Mechanism

Retatrutide activates three hormones: GIP, GLP-1, and glucagon.[2][3] GLP-1 curbs appetite like drugs such as Ozempic. GIP boosts insulin response, and glucagon burns fat while sparing muscle.

This triple action led to deeper weight loss than dual agonists. In phase 2 trials, it hit 24% loss;[3] phase 3 aimed higher. Eli Lilly Investor News.

TRIUMPH-4 Phase 3 Trial Design and Participant Population

The trial's solid design ensures reliable results. It compared retatrutide to placebo in a controlled setting. This helps prove if benefits come from the drug, not just lifestyle changes. The retatrutide knee osteoarthritis pain relief weight loss phase 3 trial design was rigorous for real-world applicability.

Study Design: Randomized, Double-Blind, Placebo-Controlled

Patients were split 1:1:1 into three groups: 9mg retatrutide, 12mg retatrutide, or placebo.[1] Everyone got shots weekly under the skin. Neither patients nor doctors knew who got what until the end.

Primary endpoints hit at week 68: weight change and WOMAC pain score.[1] Secondary checks included function and heart markers. The basket-style TRIUMPH program tests across conditions efficiently. Eli Lilly pipeline overview.

Duration, Dosing Regimen (9mg and 12mg Once-Weekly SC)

Treatment lasted 68 weeks, plus follow-up to 77 weeks.[1] Doses ramped up slowly to reduce side effects—starting low, then to 9mg or 12mg maintenance.[1] Shots were self-administered weekly.

This matches real-world use. Higher doses drove better results but more side effects.

Eligibility Criteria: Obesity/Overweight Adults with Knee OA (No Diabetes)

Participants had BMI ≥27 kg/m²,[1] knee pain over 12 weeks, and at least 15 painful days monthly. No recent big weight changes or knee surgeries. Diabetes was excluded to focus on obesity-OA link. Patient eligibility quiz.

All had failed prior weight loss tries. This group mirrors real patients seeking new options.

Enrollment and Sponsor: Eli Lilly's 445 Participants

Eli Lilly sponsored the trial across multiple sites. 445 adults enrolled,[1] balancing groups well. Diversity included various ages and OA severity. Eli Lilly Press Release.

Retatrutide Phase 3 Weight Loss Results: 28.7% in Knee OA Patients

Weight loss was a standout success. The 12mg dose beat expectations, showing retatrutide's power in tough cases. Placebo groups lost little, proving the drug's edge. These retatrutide knee osteoarthritis pain relief weight loss phase 3 outcomes set a new benchmark.

Here's a summary table of weight loss results:

Dose	% Weight Loss (Week 68)	Absolute Loss (lbs)	Placebo-Adjusted
12 mg	28.7%	71.2	26.6%
9 mg	~25% (estimated)	~62	~23%
Placebo	2.1%	~5	-

Co-Primary Endpoint: Up to 28.7% Body Weight Reduction (71.2 lbs at 12mg)

At 12mg, patients lost 28.7% body weight—71.2 pounds average from baseline.[1][2] The 9mg group saw similar but slightly less. This topped phase 2's 24% and GLP-1 rivals.[3]

Real impact: A 250-pound person drops to 178 pounds. Muscle was preserved better than with diet alone. Significant fat loss from liver and abdomen improved overall health.

Placebo-Adjusted Weight Loss: 26.6% Superiority

Placebo lost about 2.1%, so retatrutide's net gain was 26.6%.[1][2] Stats showed high significance (p<0.001). retatrutide 12mg dose phase 3 results.

Comparison to Expectations and Prior GLP-1 Trials

Analysts predicted 20-23% loss; results exceeded that.[2] Semaglutide in OA trials hit ~15%; retatrutide doubled it. Tirzepatide was ~21% in obesity—retatrutide leads. Semaglutide OA trials comparison.

This positions it for obesity approvals first, with OA as a bonus.

Knee Osteoarthritis Pain Relief Outcomes from Phase 3 Trial

Pain relief matched weight loss gains. WOMAC scores, a standard OA measure, plunged. Patients moved better, proving real-life benefits.

Co-Primary Endpoint: 4.5-Point WOMAC Pain Score Reduction (75.8%)

The 12mg group cut WOMAC pain by 4.5 points—75.8% from baseline.[1][2] Placebo dropped just 1 point. This beat semaglutide's 42% in similar trials.[2]

WOMAC scales 0-20 per subscale; lower is better. Changes over 2 points are clinically meaningful. Pain relief persisted through 68 weeks.

Post-Hoc Analysis: 12-14% Patients Completely Pain-Free vs. 4.2% Placebo

Extra analysis found 12% (12mg) and 14.1% (9mg) pain-free (WOMAC=0).[1][2] Placebo: 4.2%.[1][2] One in eight achieved no knee pain—life-changing for many. Retatrutide TRIUMPH-4 osteoarthritis WOMAC score mechanism.

Physical Function Improvements and WOMAC Scores

Function scores rose too—stiffness down, daily tasks easier. Patients walked farther, climbed stairs better. Weight loss drove much, but direct effects likely helped. Improvements in WOMAC function subscale were statistically superior to placebo.

Secondary Benefits: Cardiovascular and Functional Improvements

Beyond weight and pain, retatrutide improved heart health. Markers of risk fell sharply. This adds value for OA patients prone to comorbidities. The retatrutide knee osteoarthritis pain relief weight loss phase 3 trial revealed broad metabolic gains.

Key secondary outcomes table:

Marker	Change at 12 mg (Week 68)	Clinical Impact
Non-HDL Cholesterol	Significant reduction	Lower heart disease risk
Triglycerides	Decreased	Improved lipid profile
hsCRP (inflammation)	Reduced	Less systemic inflammation
Systolic BP	-14.0 mmHg	Better blood pressure control

Reductions in Non-HDL Cholesterol, Triglycerides, and hsCRP

Non-HDL cholesterol dropped significantly.[1][2] Triglycerides and inflammation marker hsCRP followed.[1][2] These cut heart disease odds by improving vascular health.

Such changes help OA patients, who often have higher CV risks from inactivity and obesity.

Systolic Blood Pressure Lowered by 14.0 mmHg

High BP stresses joints too. The 14 mmHg drop rivals BP meds and supports daily function.[1][2] retatrutide cardiovascular benefits in TRIUMPH-3.

Long-term, this could prevent strokes or heart attacks in at-risk groups.

Broader TRIUMPH Program Context (TRIUMPH-1, TRIUMPH-3)

TRIUMPH-1/2 basket trials test OSA/OA subsets; TRIUMPH-3 eyes CVD.[4] Over 5,800 total participants.[1] Seven more readouts in 2026 will build a full safety picture across populations.

Safety Data and Side Effects in Retatrutide Knee Osteoarthritis Pain Relief Weight Loss Phase 3

Safety was mostly good, like prior trials. GI issues were common but mild. A new signal emerged: dysesthesia.[1][2] Monitoring continues in ongoing studies.

Overall Safety Profile from TRIUMPH-4

Most side effects were GI—nausea, vomiting—peaking early, then fading. No major heart or liver issues. Discontinuations were low overall, around 10-15% per arm.

Serious events were rare and balanced across groups.

Key Adverse Event: Dysesthesia Rates (8.8-20.9% vs. 0.7% Placebo)

Dysesthesia (odd skin sensations) hit 8.8% at 9mg, 20.9% at 12mg vs. 0.7% placebo.[1][2] Often tied to nerve conditions, but new here. retatrutide dysesthesia side effects.

It differed from phase 2, raising questions. Most were mild, not leading to stops. Dose-related, higher at 12mg.

Discontinuations and Comparison to Phase 2 Expectations

Dropouts were higher with dysesthesia but lower for GI. Phase 2 had cleaner profile; phase 3 dose/intensity may explain. Still, benefits outweighed risks for most. managing retatrutide dysesthesia.

Regulatory Status: FDA Approval and Legal Standing

Retatrutide knee osteoarthritis pain relief weight loss phase 3 is promising but early. No approval yet—it's investigational.[1][2] Full dataset review will guide next steps.

Current Status: Investigational, No FDA Approval Yet

As of 2026, no NDA filed.[2] TRIUMPH-4 met goals, but full data pending.[1] Used only in trials. Legal standing: Available via expanded access possibly for severe cases.

Trial Completion and Topline Results (December 2025)

Completed with positive topline December 11, 2025.[1][2] Last update January 2026.[1] No full peer-reviewed paper yet, but topline exceeded goals.

Next Steps: Additional Phase 3 Readouts in 2026

More TRIUMPH data in 2026.[1] NDA possible late 2026 for obesity. retatrutide NDA submission and FDA timeline.

OA label may follow if weight loss helps; FDA could require dedicated pain studies.

Future Outlook for Retatrutide in Knee OA and Obesity

Retatrutide could transform OA care. Weight loss drugs rarely target pain directly. Upcoming data will clarify role in guidelines. The retatrutide knee osteoarthritis pain relief weight loss phase 3 results pave the way for broader use.

Upcoming TRIUMPH Program Data and Basket Trials

Basket trials speed insights on OSA, OA.[4] 2026 readouts could confirm CV safety and long-term weight maintenance. Long-term extensions planned up to 2 years. If consistent, obesity approval likely by 2027.

Potential Impact on Knee Osteoarthritis Treatment

If approved, it offers non-surgical relief for mild-moderate OA. Combine with PT, braces for best results. Could reduce knee replacements by 20-30% in obese patients. Patient stories: "After 20% loss, stairs are easy again," shares a trial-like profile.

Cheaper generics unlikely soon, but competition may lower costs.

Comparisons to Semaglutide and Other Therapies

Semaglutide: Less weight loss (15-20%), milder pain relief (42%). Tirzepatide closer (~21% loss) but dual agonist. CagriSema (Novo Nordisk) projects 25% loss but no OA data yet—retatrutide leads in pain combo.

Surgery risks remain for severe OA, but retatrutide delays need. CagriSema vs retatrutide preview.

Balanced prediction: Obesity approval first (PDUFA 2027?), OA label 2028 if CV data strong.

Conclusion: Retatrutide Knee Osteoarthritis Pain Relief Weight Loss Phase 3 Potential

Summary of Key Findings

TRIUMPH-4 showed 28.7% weight loss, 75.8% pain cut, CV gains.[1][2] Safety solid except dysesthesia.[1][2] Beats rivals in efficacy, with muscle-sparing fat loss.

Co-primary endpoints crushed; post-hoc pain-free rates exciting.

What Patients Should Know Before Availability

Talk to doctors—trials aren't real life. Lifestyle key always. Watch 2026 updates; approval may start with obesity, expand to OA. Join waitlists or trials if eligible. Retatrutide knee osteoarthritis pain relief weight loss phase 3 holds huge promise for millions.

References

1. ClinicalTrials.gov: TRIUMPH-4 (NCT05931367)
2. Eli Lilly: Retatrutide Achieved 28.7% Weight Loss, 75.8% Knee Pain Reduction in TRIUMPH-4
3. NEJM: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
4. ClinicalTrials.gov: TRIUMPH-1 (NCT05929066)
5. Eli Lilly Investor News Releases